Objective: Th e role of Ghrelin, also known as the appetite hormone, is not fully explained in the development of morbid obesity. Plasma Ghrelin level is low in obese and high in slim subjects. Ghrelin-expressing cells were investigated histopathologically in the stomach of morbid obese patients in this study. Tissue Ghrelin expression was also compared with various parameters such as the distribution of endocrine cells, age, gender, body mass index, preoperative plasma Ghrelin level and presence of accompanying diseases.
INTRODUCTION
Morbid obesity defi nes a severe obesity that is lifethreatening and shortens the person's life where the body mass index (BMI) is over 40. Th e most important factor responsible for the development of morbid obesity is the energy balance being distorted in favor of food intake and storage (1) . Ghrelin is one of the hormones considered to have the greatest impact on the energy balance.
Ghrelin, which is also known as the appetite hormone, was discovered by the Japanese scientist Masayasu Kojima in 1999 and is a molecule acting on many systems and thought to have an important role in the development of obesity (2, 3) . However, how the hormone ghrelin aff ects the development of morbid obesity is not yet known.
Th e aim of this study was to determine the histopathological changes seen in the stomach in morbid obesity, to evaluate the distribution of endocrine cells and ghrelin expressing cells in the stomach of these patients, and to examine the relationship between the plasma ghrelin levels and ghrelin immunoreactive cell density.
MATERIAL and METHODS
Gastric resection materials of 33 cases (24 female, 9 male) who underwent laparoscopic "sleeve" gastrectomy (LSG), also known as a "stomach tube" operation, with a diagnosis of morbid obesity at the Pamukkale University Department of General Surgery, Faculty of Medicine between 2010 and 2011 were prospectively evaluated with histopathological and immunohistochemical methods. In addition, 8 (5 males, 3 females) patients who were not "obese/morbidly obese" according to BMI and had undergone partial/total gastrectomy because of reasons other than obesity were included in the study as a control group for comparison with the patient group in terms of tissue ghrelin and Chromogranin-A expression and blood ghrelin levels,.
Th e data such as age, gender, weight, height, BMI, and presence of additional disease (diabetes, hypertension, heart disease) in the study group were obtained from the clinical fi les.
Blood samples for the plasma ghrelin level were obtained just before the operation and the measurements were performed at the Medical Biochemistry Department with a commercial Elisa method and kit (Ghrelin Enzyme Immunoassay Kit, Code: ANNEX-031-30, Phoenix Pharmaceuticals, INC.).
Resection materials were fi xed with 10% buff ered neutral formalin for 16-24 hours. On the fi xated LSG material, a total of eight samples from the standard anatomical locations (three from the proximal and middle of the resection specimen and two from the distal) were taken from each patient. Th e samples taken from the proximal end (fundus) and middle (proximal corpus) of the resection material were coded as "proximal" while the samples taken from the distal end (distal corpus) were coded as "distal" samples. Th e samples obtained were cut 4 μm thick aft er the routine tissue follow-up procedure and stained with Hematoxylin-Eosin (H&E) to be ready for microscopic examination. Th e presence of lymphoid follicle hyperplasia, interstitial lymphocytic infi ltration and congestion in the lamina propria, erosion/ulceration in the mucous surface epithelium, microvesiculation/dilatation and neutrophilic infi ltration in parietal cells and dilated gland structure in the mucosa were evaluated in detail in the proximal and distal samples. Lymphoid follicle hyperplasia in lamina propria, interstitial lymphocytic infi ltration and congestion parameters were graded semiquantitatively between 0 and 3 as (0) absent/normal range, (1) mild, (2) moderate, and (3) severe. Th e evaluation was done separately for the proximal and distal corpus. Other histological parameters (erosion/ulceration in the mucosal surface epithelium, microvesiculation/dilation and neutrophilic infi ltration in parietal cells, dilated gland structures in the mucosa) and other clinical parameters (associated diseases such as diabetes, hypertension, heart disease) were evaluated as "yes/no" for each patient.
Two blocks, one each from the proximal and distal coded samples, were selected for each patient for immunohistochemical examination. 3-micron thick sections were prepared from the selected paraffi n blocks for Ghrelin and endocrine cell determinant (Chromogranin-A) immunohistochemical analysis and the procedure was performed on a fully automated immunohistochemistry device (VEN-TANA Benchmark / LT, Ventana Medical Systems, USA). Th e sections were applied Ghrelin monoclonal antibody (Abcam, Cambridge, United Kingdom, Code: ab57222, dilution: 1/200, retrieval EDTA 60 min, 30 min. incubation) and Chromogranin-A monoclonal antibody (Th ermo Scientifi c, USA, Clone: LK2H10, dilution: 1/800, retrieval EDTA 60 min, 32 min. incubation) drops as the primary antibody to visualize the targeted proteins. Th e immunohistochemically stained sections were evaluated with the method below. ate areas containing the mucosa in full-thickness from the surface of the stomach mucosa to the muscularis mucosa. Th e total number was divided by fi ve, and the arithmetic means for both proximal and distal segments were taken. In addition, the numerical data obtained for the proximal and distal parts were added and divided into two and the mean Ghrelin immunopositive cell number in each case was obtained.
Chromogranin-A:
Th e evaluation was performed separately for the proximal and distal coded samples in each case. On light microscope (Olympus BX51) at x10 magnifi cation, chromogranin immunopositive cells were counted in 2 most appropriate area containing the mucosa in fullthickness from the surface of the stomach mucosa to the lamina muscularis mucosa. Th e total number was divided by two, and the arithmetic means for both proximal and distal segments were taken. Cases displaying too much staining to count with Chromogranin-A were also assessed in terms of endocrine cell hyperplasia (focal simple hyperplasia, simple hyperplasia, micronodular hyperplasia) and were graded in fi ve categories as follows: (chi-square) test was used for non parametric evaluations, and the t-test in independent groups, Wilcoxon and MannWhitney U tests were used for other evaluations. A p value <0.05 was accepted as signifi cant for the obtained results.
RESULTS
A total of 33 morbid obese patients (24 females, 9 males) and 8 control patients (5 males, 3 females) who were not obese were included in the study. . Th ere was no morbidly obese subject in the control group according to BMI. In terms of additional disease, 8 of the 33 obese patients (24.2%) had concurrent hypertension (HT), 9 (27.3%) had diabetes mellitus (DM), and 2 (6.1%) had coronary artery disease.
As a result of histopathological examination of LSG materials of the cases, 23 (69.7%) were evaluated as chronic gastritis, 3 as erosive gastritis (9.1%), 2 (6.1%) as chronic active gastritis, 1 as congestioned stomach tissue (3%) and 4 as normal stomach tissue (12.1%). Clinical characteristics of the patients involved in the study are summarized in Table  I and the histopathological fi ndings in Figure 1A -D.
Th e distribution of the histopathological lesions we observed in LSG resection materials were microvesiculation/ dilatation in parietal cells in 57.6%, erosion/ulceration in the mucosal surface epithelium in 57.6%, dilated gland structure in the mucosa in 57.6% and neutrophilic infi ltration in 6.1%. In addition, moderate-to-severe lymphoid follicle hyperplasia was detected in the lamina propria in 20 patients (60.7%), interstitial lymphocytic infi ltration in 21 patients (63.6%) and mucosal congestion in 14 patients (42.4%). Th e presence of Helicobacter pylori was not investigated in resection materials. Th e distribution of observed histopathological fi ndings showed no signifi cant diff erence in the proximal and distal gastric corpus mucosa. No significant correlation was detected between the histopathological fi ndings and the parameters evaluated in obese patients, other clinical fi ndings, immunohistochemical fi ndings and plasma Ghrelin levels.
When the number of immunopositive ghrelin cells was evaluated in the general population including the patient and control group (41 subjects in total), it was signifi cantly higher in the proximal corpus part of the stomach than the distal corpus part (Wilcoxon test, p=0.0001, Figure 2) . Th e number of Ghrelin immunopositive cells in the gastric mucosa in females was found to be signifi cantly higher than males (73.14 ± 23.71 vs. 54.57 ± 16.51, Mann-Whitney U test, p=0.007, Table II ).
Th ere was no signifi cant diff erence between the control group and the patient group in terms of the preoperative plasma Ghrelin levels, Ghrelin immunopositive cell numbers and the staining severity.
No signifi cant relation was found between Ghrelin or Chromogranin-A immunopositive cell distribution or preoperative plasma Ghrelin level -endocrine cell hyperplasia. No statistically signifi cant diff erence was found between the two genders in terms of the preoperative plasma Ghrelin level. shows many of its physiological eff ects in this way. It is mainly eff ective on carbohydrate and energy metabolism, pancreatic exocrine and endocrine function, gastrointestinal system, eating and the cardiovascular system (2). It is thought to have autocrine/paracrine eff ects in many tumor tissues. Intravenous Ghrelin injection increases gastric acid secretion and gastric motility proportional to the dose. Ghrelin is thought to aff ect gastric functions via the vagus nerve.
Sakata et al. investigated Ghrelin-producing cells in the gastrointestinal system by the immunohistochemical method. Th e Ghrelin-immunopositive cells were detected to be mostly localized in the stomach and less in the duodenum, jejunum, ileum, cecum, and colon (6) . Ghrelin is mainly synthesized in X/A-like cells that are specialized endocrine cells in the gastric oxyntic mucosa. Th ese cells are localized in the full thickness of the oxyntic gastric mucosa and topographically correlate with parietal cells (5) . Ghrelin immunopositive cells were seen only in the mucosal layer of the stomach, in the gastric glands of the lamina propria in our study. In a study by Stenstrom et al., the stomach section that contains the oxyntic mucosa was surgically removed in rats and the Ghrelin concentration in the circulation was found to be reduced by 80% (7).
In the gastrointestinal system, Ghrelin immunoreactive cell density decreases from proximal to distal. When we No signifi cant relation was found between the presence of associated diseases (DM and HT) and the Ghrelin immunopositive cell number or preoperative plasma Ghrelin level.
DISCUSSION
Obesity is now a major health problem with an impact on mortality and morbidity and compromises the sociocultural life of the person. It ranks second among deaths with an unknown cause. Bariatric surgery off ers the best treatment for sustained weight loss in morbidly obese patients at present (4).
Many factors are responsible for the development of morbid obesity. However, the most important factor is the distortion of the energy balance in favor of nutrient intake and storage. Many organs, particularly the hypothalamus, take part in ensuring the balance and some specifi c peptides allow communication between these tissues. Ghrelin is one of the most important of these peptides.
Ghrelin is an orexigenic peptide that increases appetite and thus food intake, and is a hormone that has been found to contribute to maintaining the energy balance. Ghrelin was found in 1999 by the Japanese scientist Masayasu Kojima and his team that worked in the cardiovascular area and is mainly released from the fundus of the stomach (2). It also causes growth hormone secretion from pituitary and 
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Wang and Liu, in the study they conducted by using the clinical data of obese patients who underwent LSG, determined that the patients lost 60% of their excess weight in the 2-year follow-up (14) .
A number of studies that report various fi ndings and results about the relationship of plasma Ghrelin level with age, gender, and BMI are present in the literature. We found no statistically signifi cant relationship between ghrelin immunopositive cell numbers and the age of the patient, BMI or plasma Ghrelin levels. On the other hand, we also could not fi nd any statistically signifi cant relationship between the preoperative plasma Ghrelin level and gender.
However, the number of Ghrelin immunopositive cells in the gastric mucosa in females were signifi cantly higher than males in our study when we evaluated a total of 41 patients. Th ere is no similar study previously conducted in the literature regarding this situation we determined so we think this result is signifi cant in terms of the morbid obesity treatment method choice.
Purnell et al. reported a positive relation between starvation Ghrelin level and age similar to our study in a study they conducted in a population consisting of 60 adult males and females with a wide age and weight range. However, unlike our result, they found the fasting Ghrelin level to be negatively related to the BMI, to be similar in males and females and not change with the menopausal status (15).
Zou et al. reported the plasma Ghrelin level to show negative correlation with BMI and have no relation with factors such as age and gender in their study on 283 subjects (16).
Chuang et al. found plasma Ghrelin levels to be similar in males and females in cases not accompanied by HP infection in their study on 341 patients with dyspepsia. Among patients positive for HP, the plasma Ghrelin levels were found to be lower in males. In addition, a strong correlation was found between HP infection and acute and chronic infl ammation scores associated with it and lower Ghrelin levels but only in males (17) . Our chromogranin-A immunohistochemical analysis performed to evaluate the distribution of endocrine cells in LSG resection material revealed a mild increase in endocrine cells in 13 patients (39.4%), focal simple hyperplasia in 3 patients (9.1%), analyzed a total of 41 cases, a signifi cantly higher number of Ghrelin immunopositive cells were detected in the fundus-proximal corpus part of the stomach than the distal corpus part in our study, in conformance with other studies. Tanaka-Shintani and Watanabe took samples from the small curvature area of the stomach without a tumor in 30 patients with gastric cancer and examined the Ghrelin expression immunohistochemically. Th ey found Ghrelinimmunoreactive cells in all parts of the stomach, but mostly in the fundus area (5). Lee et al. found the highest expression in terms of immunolocalization of Ghrelin in diff erent areas in the fundus in rats (8) .
Th e main regulator of the plasma Ghrelin level is food intake. Th e level rises in starvation and causes the person to eat, while it is suppressed aft er eating and the level falls. Oral or intravenous glucose administration decreases plasma Ghrelin levels (9,10). Sönmez and Ozan, in their study on rats, found the number of Ghrelin cells in the stomach in starvation to be increased compared to the control group; the number of cells showing immunoreactivity decreased and regressed to values close to the control group following re-feeding aft er starvation (11) . Th e plasma Ghrelin level was not investigated in that study.
Although Ghrelin is known as the appetite hormone, plasma Ghrelin levels and the BMI interestingly show an inverse relationship. Ghrelin secretion was observed to be increased in anorexia and cachexia, decreased in obesity, and normal in ideal body weight (12) .
In a study of Vrabie et al. with features similar to our study, the main histopathological gastric lesions in obese patients who had underwent LSG were investigated. Th e majority of patients, as in our study group, were reported to be young and female. Gastric resection material was obtained from 87 surgical interventions where LSG was performed between 2007 and 2008, and the most common histological microscopic lesions were parietal cell hyperplasia (63.2%), ulceration (34.5%), lymph node hyperplasia in the lamina propria (33.3%), active gastritis (23%), and other lesions (10.3%) (13) . We have found no hyperplasia in the parietal cells but microvesiculation and dilatation were observed.
Th e LSG operation "suppresses" Ghrelin levels and thereby reduces appetite and increases weight loss in obese patients. with LSG, and we can say that Ghrelin is a hormone closely linked with obesity taking into account the marked loss in appetite in the period aft er LSG. Th e higher number of cells expressing Ghrelin in the proximal of stomach in our study is consistent with the results of other relevant studies. In addition, there is no similar study in the literature reporting the detection of a higher number of cells expressing Ghrelin in the gastric mucosa in females than in males. We believe this result may be important in the choice of treatment of morbid obesity. However, new studies are required to prove this hypothesis.
simple hyperplasia in 7 patients (21.2%) and micronodular hyperplasia in 3 patients (9.1%). Seven patients (21.2%) were considered to be within the normal range of endocrine cell density. With these fi ndings, a signifi cant relation was found neither between Ghrelin and chromogranin-A immunopositive endocrine cell distribution nor between the preoperative plasma Ghrelin level and endocrine cell hyperplasia. Our results in this respect were consistent with several previous studies in the literature (18) (19) (20) .
We found Ghrelin immunopositive cell number to be signifi cantly lower in 9 obese patients with DM than in patients without DM, similar to the study of Maghsoud et al. (21) . In addition, although the preoperative plasma Ghrelin level was found to be higher in non-diabetic patients, the diff erence was not statistically signifi cant.
Pöykkö et al. obtained blood samples from 1040 subjects in their study to determine whether low blood Ghrelin concentration was a risk factor for type 2 DM. Th ey found low Ghrelin levels related to type 2 DM, high insulin concentration, insulin resistance and increased blood pressure (22) .
Bideci et al. compared the plasma Ghrelin levels of 27 child patients with type 1 diabetes and 25 healthy children. Th ey reported the Ghrelin levels to be similar and normal in the control group and the group of patients with type 1 diabetes (23).
Th ere are various opinions on the relationship between plasma Ghrelin concentrations and HT in the literature. Although we found the preoperative plasma Ghrelin level to be higher in patients with HT than non-HT patients, the diff erence was not statistically signifi cant. In the previously mentioned study of Pöykkö et al., low blood ghrelin concentration was reported to be a risk factor for HT and ghrelin levels were negatively associated with systolic and diastolic blood pressure. Th us, they argued that Ghrelin may have a role in type 2 DM etiology and regulation of blood pressure (22) . İyidoğan et al. reported Ghrelin to be positively associated with HT in obese women and an inverse relationship developed with the increase in BMI (24) .
LSG is an important obesity surgery which is eff ective in a short time and with growing popularity in obesity surgery. Th e superior clinical results with LSG have focused attention on the partial gastric resection option and possible eff ects of mediators released from the resected portion. Th e role of the Ghrelin hormone in the development of morbid obesity is not yet known. However, we think that especially the Ghrelin-producing fundus area is removed
